Sigachi Industries Advances Cystic Fibrosis APIs with ₹250 Crore Potential
Filing Summary
Sigachi Industries Ltd. has announced a significant milestone in its research and development efforts with the advancement of a new combination of Cystic Fibrosis Active Pharmaceutical Ingredients (APIs) comprising Vanzacaftor, Tezacaftor, and Deutivacaftor. The company projects an annual revenue potential of approximately ₹250 crore starting from Q4 FY2026–27. This development aligns with Sigachi’s strategic focus on high-value specialty APIs. The company is exploring strategic collaborations for R&D and commercial supply, with innovator patent protection for Vanzacaftor extending until 2039, ensuring long-term revenue stability.
Sigachi Industries Ltd. has announced a significant advancement in its research and development pipeline with the successful development of a new combination of Cystic Fibrosis (CF) Active Pharmaceutical Ingredients (APIs). The combination includes Vanzacaftor, Tezacaftor, and Deutivacaftor. This milestone is part of Sigachi’s strategic focus on expanding its presence in complex, high-value specialty APIs.
The company has identified an annual revenue potential of approximately ₹250 crore commencing from Q4 FY2026–27. This projection is based on internal market assessments and strategic evaluations. Sigachi is actively exploring strategic collaborations with formulation innovators for research and development as well as future commercial supply of these CF APIs. The company aims to leverage these partnerships to enhance its market position in the CF therapeutic segment.
The new CF API combination involves advanced chemistry, multi-step synthesis, and specialized reactions. These factors contribute to high technological complexity and significant barriers to entry, which limit competitive intensity. This development reinforces Sigachi’s capabilities in complex API manufacturing. The company is focused on strengthening its core businesses while selectively scaling innovation-driven, high-value opportunities aligned with its long-term growth strategy.
The global cystic fibrosis therapeutics market is estimated to exceed USD 10 billion. This growth is driven by the adoption of next-generation modulator therapies, long-term treatment requirements, and strong pricing resilience. Sigachi’s entry into CF APIs positions the company in a structurally strong and innovation-led therapeutic segment with long-term demand visibility. The innovator patent protection for Vanzacaftor extends until 2039, providing sustained collaboration-led commercial opportunities and revenue stability within the cystic fibrosis therapeutic space.
The company anticipates commencing revenue generation from this portfolio in Q4 FY2026–27. Sigachi is actively pursuing strategic collaborations to facilitate the R&D and commercial supply of these APIs. The company continues to focus on strengthening its core businesses while selectively scaling innovation-driven, high-value opportunities aligned with its long-term growth strategy.
Sigachi Industries Ltd. is a global player in the pharmaceutical industry, focusing on advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O&M) services. The company operates multiple facilities across Telangana, Gujarat, and Karnataka. With a strong focus on innovation, quality, and regulatory compliance, Sigachi leverages cutting-edge technology and global expertise to develop high-value pharma, food, and nutrition solutions. The company collaborates with healthcare partners, regulatory bodies, and global stakeholders to expand access to reliable, high-quality pharmaceutical ingredients.